NYSEMKT: SENSSenseonics Holdings Inc Stock
$0.49-0.01 (-2%)
Updated Jul 9, 2025
SENS Price
$0.49
Fair Value Price
N/A
Market Cap
$322.57M
52 Week Low
$0.25
52 Week High
$1.40
P/E
-4.48x
P/B
9.16x
P/S
19.92x
PEG
N/A
Dividend Yield
N/A
Revenue
$23.68M
Earnings
-$74.00M
Gross Margin
7.2%
Operating Margin
-279.45%
Profit Margin
-312.5%
Debt to Equity
1.48
Operating Cash Flow
-$56M
Beta
1.78
Next Earnings
Aug 7, 2025
Ex-Dividend
N/A
Next Dividend
N/A
SENS Overview
Senseonics Holdings, Inc., a medical technology company, develops and commercializes continuous glucose monitoring (CGM) systems for people with diabetes primarily in Europe. Its products include Eversense and Eversense XL, which are implantable CGM systems to measure glucose levels in people with diabetes for a period of up to 90 and 180 days. Senseonics Holdings, Inc. was founded in 1996 and is headquartered in Germantown, Maryland.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine SENS's potential to beat the market
- SENS doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Medical Device
Industry Rating
C
SENS
RankedUnranked of 104
RankedUnranked of 104
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $12.28 | A | |
| $231.28 | A | |
| $30.69 | A |
Be the first to know about important SENS news, forecast changes, insider trades & much more!
SENS News
Overview
Due Diligence Score
–
Industry Average (27)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how SENS scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
SENS is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
SENS is poor value based on its book value relative to its share price (9.16x), compared to the US Medical Devices industry average (4.08x)
P/B vs Industry Valuation
SENS is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more SENS due diligence checks available for Premium users.
Valuation
SENS price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-4.48x
Industry
35.9x
Market
30.63x
SENS price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
9.16x
Industry
4.08x
SENS is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
SENS's financial health
Profit margin
Revenue
$6.3M
Net Income
-$14.3M
Profit Margin
-227.9%
SENS's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
SENS's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$87.2M
Liabilities
$52.0M
Debt to equity
1.48
SENS's short-term assets ($78.37M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
SENS's short-term assets ($78.37M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
SENS's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
SENS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$16.1M
Investing
-$25.3M
Financing
$6.1M
SENS's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
SENS vs Medical Device Stocks
Senseonics Holdings Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.